MAPK3 and plasma cell myeloma: Yao et al. showed that SPRY2 regulates proliferation and survival of multiple myeloma via inhibiting the activation of ERK1/2 pathway, while Kumar et al. identified SPRY4 as the potential mediator of growth suppression in melanoma upon dual BRAFV600E and NRASQ61 oncogene expression [41,42].